Literature DB >> 19554612

APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure.

Lynn M Bekris1,2, Nichole M Galloway1, Thomas J Montine3, Gerard D Schellenberg4, Chang-En Yu1,2.   

Abstract

Currently the epsilon4 allele of the apolipoprotein E gene (APOE) is the strongest genetic risk factor for late onset Alzheimer's disease (AD). However, inheritance of the APOE epsilon4 allele is not necessary or sufficient for the development of AD. Genetic evidence suggests that multiple loci in a 70 kb region surrounding APOE are associated with AD risk. Even though these loci could represent surrogate markers in linkage disequilibrium with APOE epsilon4 allele, they could also contribute biological effects independent of the APOE epsilon4 allele. Our previous study identified multiple SNPs upstream from APOE that are associated with cerebrospinal fluid apoE levels, suggesting that a haplotype structure proximal to APOE can influence apoE expression. In this study, we examined apoE expression in human post-mortem brain (PMB), and constructed chromosome-phase-separated haplotypes of the APOE proximal region to evaluate their effect on PMB apoE expression. ApoE protein expression was found to differ among AD brain regions and to differ between AD and control hippocampus. In addition, an extended APOE proximal haplotype structure, spanning from the TOMM40 gene to the APOE promoter, may modulate apoE expression in a brain region-specific manner and may influence AD disease status. In conclusion, this haplotype-phenotype analysis of apoE expression in PMB suggests that either; (1) the cis-regulation of APOE expression levels extends far upstream of the APOE promoter or (2) an APOE epsilon4 allele independent mechanism involving the TOMM40 gene plays a role in the risk of AD. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19554612      PMCID: PMC2829359          DOI: 10.1002/ajmg.b.30993

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  48 in total

1.  Distortion of allelic expression of apolipoprotein E in Alzheimer's disease.

Authors:  J C Lambert; J Pérez-Tur; M J Dupire; D Galasko; D Mann; P Amouyel; J Hardy; A Delacourte; M C Chartier-Harlin
Journal:  Hum Mol Genet       Date:  1997-11       Impact factor: 6.150

2.  Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene.

Authors:  M J Artiga; M J Bullido; I Sastre; M Recuero; M A García; J Aldudo; J Vázquez; F Valdivieso
Journal:  FEBS Lett       Date:  1998-01-09       Impact factor: 4.124

3.  APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.

Authors:  Wenyong Huang; Chengxuan Qiu; Eva von Strauss; Bengt Winblad; Laura Fratiglioni
Journal:  Arch Neurol       Date:  2004-12

4.  Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent.

Authors:  U Beffert; J S Cohn; C Petit-Turcotte; M Tremblay; N Aumont; C Ramassamy; J Davignon; J Poirier
Journal:  Brain Res       Date:  1999-10-02       Impact factor: 3.252

5.  Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease.

Authors:  B T Hyman; T Gomez-Isla; G W Rebeck; M Briggs; H Chung; H L West; S Greenberg; S Mui; S Nichols; R Wallace; J H Growdon
Journal:  Ann N Y Acad Sci       Date:  1996-12-16       Impact factor: 5.691

6.  Specific regional transcription of apolipoprotein E in human brain neurons.

Authors:  P T Xu; J R Gilbert; H L Qiu; J Ervin; T R Rothrock-Christian; C Hulette; D E Schmechel
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

7.  Allelic expression of APOE in human brain: effects of epsilon status and promoter haplotypes.

Authors:  Nicholas J Bray; Luke Jehu; Valentina Moskvina; Joseph D Buxbaum; Stella Dracheva; Vahram Haroutunian; Julie Williams; Paul R Buckland; Michael J Owen; Michael C O'Donovan
Journal:  Hum Mol Genet       Date:  2004-09-22       Impact factor: 6.150

8.  Regionally specific neuronal expression of human APOE gene in transgenic mice.

Authors:  P T Xu; J R Gilbert; H L Qiu; T Rothrock-Christian; D L Settles; A D Roses; D E Schmechel
Journal:  Neurosci Lett       Date:  1998-04-24       Impact factor: 3.046

9.  Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease.

Authors:  J C Lambert; C Berr; F Pasquier; A Delacourte; B Frigard; D Cottel; J Pérez-Tur; V Mouroux; M Mohr; D Cécyre; D Galasko; C Lendon; J Poirier; J Hardy; D Mann; P Amouyel; M C Chartier-Harlin
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

10.  The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.

Authors:  T Town; D Paris; D Fallin; R Duara; W Barker; M Gold; F Crawford; M Mullan
Journal:  Neurosci Lett       Date:  1998-08-14       Impact factor: 3.046

View more
  35 in total

1.  A comprehensive genetic association study of Alzheimer disease in African Americans.

Authors:  Mark W Logue; Matthew Schu; Badri N Vardarajan; Jacki Buros; Robert C Green; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Rhonna Shatz; Amy Borenstein; L Adrienne Cupples; Kathryn L Lunetta; M Daniele Fallin; Clinton T Baldwin; Lindsay A Farrer
Journal:  Arch Neurol       Date:  2011-12

Review 2.  The Alzheimer's disease mitochondrial cascade hypothesis.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease.

Authors:  Steven G Potkin; Guia Guffanti; Anita Lakatos; Jessica A Turner; Frithjof Kruggel; James H Fallon; Andrew J Saykin; Alessandro Orro; Sara Lupoli; Erika Salvi; Michael Weiner; Fabio Macciardi
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

4.  TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.

Authors:  Su Hee Chu; Kathryn Roeder; Robert E Ferrell; Bernie Devlin; Mary Ann A DeMichele-Sweet; M Ilyas Kamboh; Oscar L Lopez; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2011-08-05       Impact factor: 4.673

5.  A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.

Authors:  A D Roses; M W Lutz; H Amrine-Madsen; A M Saunders; D G Crenshaw; S S Sundseth; M J Huentelman; K A Welsh-Bohmer; E M Reiman
Journal:  Pharmacogenomics J       Date:  2009-12-22       Impact factor: 3.550

Review 6.  Role of endolysosomes and inter-organellar signaling in brain disease.

Authors:  Zahra Afghah; Xuesong Chen; Jonathan D Geiger
Journal:  Neurobiol Dis       Date:  2019-11-09       Impact factor: 5.996

7.  BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Authors:  Boris Decourt; Amanda Gonzales; Thomas G Beach; Michael Malek-Ahmadi; Aaron Walker; Lucia Sue; Douglas G Walker; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-03       Impact factor: 3.498

8.  The alternative splicing of the apolipoprotein E gene is unperturbed in the brains of Alzheimer's disease patients.

Authors:  James D Mills; Pamela J Sheahan; Donna Lai; Jillian J Kril; Michael Janitz; Greg T Sutherland
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

Review 9.  APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease.

Authors:  Andrew B Wolf; Richard J Caselli; Eric M Reiman; Jon Valla
Journal:  Neurobiol Aging       Date:  2012-11-16       Impact factor: 4.673

10.  TOMM40 rs2075650 may represent a new candidate gene for vulnerability to major depressive disorder.

Authors:  Martyn McFarquhar; Rebecca Elliott; Shane McKie; Emma Thomas; Darragh Downey; Krisztina Mekli; Zoltan G Toth; Ian M Anderson; J F William Deakin; Gabriella Juhasz
Journal:  Neuropsychopharmacology       Date:  2014-01-29       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.